Alkermes Plc Ord (NASDAQ:ALKS)’s Trend Unknown, Especially After Increased Shorts

November 14, 2017 - By Darrin Black

 Alkermes Plc Ord (NASDAQ:ALKS)’s Trend Unknown, Especially After Increased Shorts

Investors sentiment increased to 1.12 in Q2 2017. Its up 0.01, from 1.11 in 2017Q1. It is positive, as 33 investors sold Alkermes Plc shares while 72 reduced holdings. 41 funds opened positions while 77 raised stakes. 143.16 million shares or 1.87% more from 140.52 million shares in 2017Q1 were reported.
The Missouri-based Jag Capital Mngmt Ltd Liability has invested 2.19% in Alkermes Plc (NASDAQ:ALKS). Granahan Inv Mngmt Ma holds 0.82% of its portfolio in Alkermes Plc (NASDAQ:ALKS) for 154,005 shares. Archford Capital Strategies Ltd holds 0% or 43 shares in its portfolio. Eqis Capital Inc accumulated 8,292 shares. Alabama-based Andra Ap has invested 0.03% in Alkermes Plc (NASDAQ:ALKS). Suntrust Banks has 0.01% invested in Alkermes Plc (NASDAQ:ALKS) for 18,238 shares. X Management Ltd Liability Corp has 0% invested in Alkermes Plc (NASDAQ:ALKS). Insight Research Mgmt Inc accumulated 3,994 shares. Advisory Ltd Limited Liability Company holds 244 shares or 0% of its portfolio. Sumitomo Mitsui Asset Mngmt Limited reported 11,262 shares. 192,952 were reported by Utd Automobile Association. Bnp Paribas Arbitrage Sa accumulated 0.01% or 32,564 shares. Cibc Asset Mgmt owns 6,090 shares. M&T Bank & Trust stated it has 7,135 shares. Ny State Common Retirement Fund has invested 0.03% in Alkermes Plc (NASDAQ:ALKS).

The stock of Alkermes Plc Ord (NASDAQ:ALKS) registered an increase of 9.67% in short interest. ALKS’s total short interest was 7.53M shares in November as published by FINRA. Its up 9.67% from 6.86M shares, reported previously. With 1.21 million shares average volume, it will take short sellers 6 days to cover their ALKS’s short positions. The short interest to Alkermes Plc Ord’s float is 4.99%.

About 559,305 shares traded. Alkermes Plc (NASDAQ:ALKS) has risen 47.50% since November 14, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Alkermes plc is a biopharmaceutical company. The company has market cap of $7.43 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Among 13 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Alkermes had 33 analyst reports since September 1, 2015 according to SRatingsIntel. Cowen & Co maintained Alkermes Plc (NASDAQ:ALKS) rating on Friday, October 27. Cowen & Co has “Buy” rating and $63.0 target. The firm has “Overweight” rating by Barclays Capital given on Wednesday, July 13. The rating was upgraded by JP Morgan to “Overweight” on Friday, October 21. The stock has “Outperform” rating by Leerink Swann on Friday, October 21. The rating was maintained by Mizuho with “Buy” on Friday, October 20. Morgan Stanley upgraded Alkermes Plc (NASDAQ:ALKS) rating on Tuesday, September 1. Morgan Stanley has “Overweight” rating and $85 target. The firm has “Hold” rating given on Thursday, October 26 by Cantor Fitzgerald. Barclays Capital maintained Alkermes Plc (NASDAQ:ALKS) on Wednesday, October 7 with “Overweight” rating. Barclays Capital maintained the shares of ALKS in report on Friday, July 29 with “Overweight” rating. The firm has “Neutral” rating given on Thursday, January 21 by JP Morgan.

More notable recent Alkermes Plc (NASDAQ:ALKS) news were published by: which released: “Alkermes plc Reports Third Quarter 2017 Financial Results” on October 26, 2017, also with their article: “Senator Investigates How Drugmaker Alkermes Pushed Its Opioid-Addiction Treatment” published on November 06, 2017, published: “Alkermes Plc’s (ALKS) CEO Richard Pops on Q3 2017 Results – Earnings Call …” on October 26, 2017. More interesting news about Alkermes Plc (NASDAQ:ALKS) were released by: and their article: “Alkermes Stands To Gain From Revenue Increase, Upcoming NDA Submission” published on October 16, 2017 as well as‘s news article titled: “ACT NOW: Monteverde & Associates PC Announces an Investigation of Alkermes plc …” with publication date: November 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.